BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarialioglu F, Erbay A, Demir S. Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy. Pediatr Blood Cancer. 2010;55:1433-1434. [PMID: 20981697 DOI: 10.1002/pbc.22691] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Emre S, Umman V, Rodriguez-davalos M. Current concepts in pediatric liver tumors: Current concepts in pediatric liver tumors. Pediatric Transplantation 2012;16:549-63. [DOI: 10.1111/j.1399-3046.2012.01704.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
2 Frommelt P, Juern A, Siegel D, Holland K, Seefeldt M, Yu J, Uhing M, Wade K, Drolet B. Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. Pediatr Dermatol 2016;33:405-14. [DOI: 10.1111/pde.12869] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
3 Rubinstein JC, Christison-lagay ER. Successful treatment of visceral infantile hemangioma of the omentum and mesentery with propranolol. Journal of Pediatric Surgery Case Reports 2014;2:302-4. [DOI: 10.1016/j.epsc.2014.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Liu C, Zhao Z, Guo S, Zhang L, Fan X, Zheng J. Exosomal miR-27a-3p derived from tumor-associated macrophage suppresses propranolol sensitivity in infantile hemangioma. Cell Immunol 2021;370:104442. [PMID: 34634611 DOI: 10.1016/j.cellimm.2021.104442] [Reference Citation Analysis]
5 Blei F. Literature Watch. Lymphatic Research and Biology 2011;9:65-72. [DOI: 10.1089/lrb.2011.9103] [Reference Citation Analysis]
6 Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, Modiano JF, Kokta V, Boucheron LE, Mitchell DC, Bryan BA. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One. 2013;8:e60021. [PMID: 23555867 DOI: 10.1371/journal.pone.0060021] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
7 Avagyan S, Klein M, Kerkar N, Demattia A, Blei F, Lee S, Rosenberg HK, Arnon R. Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma. J Pediatr Gastroenterol Nutr 2013;56:e17-20. [PMID: 22331019 DOI: 10.1097/MPG.0b013e31824e50b7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
8 Madan N, Arnon R, Arnon R. Evaluation of cardiac manifestations in pediatric liver transplant candidates: Cardiac evaluation children pre-liver transplant. Pediatric Transplantation 2012;16:318-28. [DOI: 10.1111/j.1399-3046.2012.01667.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Gnarra M, Behr G, Kitajewski A, Wu JK, Anupindi SA, Shawber CJ, Zavras N, Schizas D, Salakos C, Economopoulos KP. History of the infantile hepatic hemangioma: From imaging to generating a differential diagnosis. World J Clin Pediatr 2016; 5(3): 273-280 [PMID: 27610342 DOI: 10.5409/wjcp.v5.i3.273] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
10 Kozanoglu I, Yandim MK, Cincin ZB, Ozdogu H, Cakmakoglu B, Baran Y. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. J Cancer Res Clin Oncol 2013;139:327-35. [DOI: 10.1007/s00432-012-1331-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
11 Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, Chun RH, Garzon MC, Holland KE, Liberman L. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128-140. [PMID: 23266923 DOI: 10.1542/peds.2012-1691] [Cited by in Crossref: 304] [Cited by in F6Publishing: 219] [Article Influence: 30.4] [Reference Citation Analysis]
12 Thompson PA, Chintagumpala M. Renal and hepatic tumors in the neonatal period. Semin Fetal Neonatal Med. 2012;17:216-221. [PMID: 22595862 DOI: 10.1016/j.siny.2012.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
13 Zhu Z, Cai P, Zhu J, Chen J, Wu B, Gu Z, Huang S, Wang J. Neonatal giant hepatic hemangioma: A case report. Medicine (Baltimore) 2018;97:e12863. [PMID: 30334996 DOI: 10.1097/MD.0000000000012863] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Lou Y, Peng WJ, Cao Y, Cao DS, Xie J, Li HH. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014;78:44-57. [PMID: 24033819 DOI: 10.1111/bcp.12235] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
15 Hsu TC, Wang JD, Chen CH, Chang TK, Wang TM, Chou CM, Lin HK. Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants. Pediatr Neonatol 2012;53:125-32. [PMID: 22503260 DOI: 10.1016/j.pedneo.2012.01.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
16 Kwon EK, Seefeldt M, Drolet BA. Infantile hemangiomas: an update. Am J Clin Dermatol 2013;14:111-23. [PMID: 23338947 DOI: 10.1007/s40257-013-0008-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
17 Bosemani T, Puttgen KB, Huisman TA, Tekes A. Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. Eur J Pediatr. 2012;171:1023-1028. [PMID: 22234480 DOI: 10.1007/s00431-011-1671-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
18 Fernández Ibieta M, Méndez Aguirre NA, Girón Vallejo O, Ruiz Jiménez JI. [Rapid response of a multifocal liver hemangioma to propranolol treatment]. An Pediatr (Barc) 2013;79:122-3. [PMID: 23402776 DOI: 10.1016/j.anpedi.2012.10.013] [Reference Citation Analysis]
19 Oksiuta M, Matuszczak E, Debek W, Dzienis-koronkiewicz E, Hermanowicz A. Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. The Journal of Maternal-Fetal & Neonatal Medicine 2014;29:64-8. [DOI: 10.3109/14767058.2014.986650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Craiglow BG, Antaya RJ. Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches. Paediatr Drugs 2013;15:133-8. [PMID: 23456550 DOI: 10.1007/s40272-013-0008-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
21 Delmotte N, Curti C, Montana M, Crozet M, Vanelle P, Gensollen S. [News on infantile hemangioma therapy by beta-blocker]. Therapie 2012;67:257-65. [PMID: 22874493 DOI: 10.2515/therapie/2012033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Sánchez-carpintero I, Ruiz-rodriguez R, López-gutiérrez J. Propranolol en hemangiomas infantiles: eficacia clínica, riesgos y recomendaciones. Actas Dermo-Sifiliográficas 2011;102:766-79. [DOI: 10.1016/j.ad.2011.05.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
23 Işeri OD, Sahin FI, Terzi YK, Yurtcu E, Erdem SR, Sarialioglu F. beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration. Pharm Biol 2014;52:1374-81. [PMID: 25026350 DOI: 10.3109/13880209.2014.892513] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
24 Morais P, Magina S, Mateus M, Trindade E, Jesus JM, Azevedo F. Efficacy and safety of propranolol in the treatment of parotid hemangioma. Cutan Ocul Toxicol 2011;30:245-8. [PMID: 21338243 DOI: 10.3109/15569527.2011.554483] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
25 Ni N, Guo S, Langer P. Current concepts in the management of periocular infantile (capillary) hemangioma. Curr Opin Ophthalmol 2011;22:419-25. [PMID: 21730838 DOI: 10.1097/ICU.0b013e32834994b4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
26 Sana L, Betalli P, Bravi M, Stroppa P, Cheli M, Sonzogni A, Licini L, Agazzi R, Colledan M, Parolini F, Alberti D, D'Antiga L. Hepatic hemangioendothelioma of infancy: clinical features of a large cohort of patients and proposed management. Pediatr Surg Int 2021;37:791-7. [PMID: 33515109 DOI: 10.1007/s00383-021-04860-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]